Javelin’s Intranasal Morphine Meets Phase III Primary Endpoint
This article was originally published in The Pink Sheet Daily
Executive Summary
Morphine delivered using Javelin’s proprietary technology could offer simpler, effective alternative to other postoperative opioids, firm says.